IL165398A0 - Method for identifying immunoreactive peptides - Google Patents

Method for identifying immunoreactive peptides

Info

Publication number
IL165398A0
IL165398A0 IL16539803A IL16539803A IL165398A0 IL 165398 A0 IL165398 A0 IL 165398A0 IL 16539803 A IL16539803 A IL 16539803A IL 16539803 A IL16539803 A IL 16539803A IL 165398 A0 IL165398 A0 IL 165398A0
Authority
IL
Israel
Prior art keywords
peptides
immunoreactive peptides
identifying
tumorous
identifying immunoreactive
Prior art date
Application number
IL16539803A
Other languages
English (en)
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of IL165398A0 publication Critical patent/IL165398A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
IL16539803A 2002-05-29 2003-05-14 Method for identifying immunoreactive peptides IL165398A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225139A DE10225139A1 (de) 2002-05-29 2002-05-29 Verfahren zur Identifizierung von immunreaktiven Peptiden
PCT/EP2003/005038 WO2003100432A2 (de) 2002-05-29 2003-05-14 Verfahren zur identifizierung von immunreaktiven peptiden

Publications (1)

Publication Number Publication Date
IL165398A0 true IL165398A0 (en) 2006-01-15

Family

ID=29557590

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16539803A IL165398A0 (en) 2002-05-29 2003-05-14 Method for identifying immunoreactive peptides
IL165398A IL165398A (en) 2002-05-29 2004-11-25 Method for identifying immunoreactive peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL165398A IL165398A (en) 2002-05-29 2004-11-25 Method for identifying immunoreactive peptides

Country Status (13)

Country Link
EP (1) EP1508047B1 (da)
JP (1) JP2005535299A (da)
AT (1) ATE403874T1 (da)
AU (1) AU2003236645B2 (da)
CA (1) CA2486738C (da)
CY (1) CY1108358T1 (da)
DE (2) DE10225139A1 (da)
DK (1) DK1508047T3 (da)
ES (1) ES2311710T3 (da)
IL (2) IL165398A0 (da)
PT (1) PT1508047E (da)
SI (1) SI1508047T1 (da)
WO (1) WO2003100432A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782070B1 (en) * 2004-06-17 2010-09-08 MannKind Corporation Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
JP2020522479A (ja) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 個別化された癌ワクチンを作製する方法
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
PE20240779A1 (es) 2021-07-27 2024-04-17 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a ct45
CN121358777A (zh) 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025168848A1 (en) 2024-02-09 2025-08-14 IMMUNEO Therapeutics GmbH Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same
LU103243B1 (en) 2024-02-09 2025-08-11 PMCR GmbH Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025233432A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
WO2026008886A1 (en) 2024-07-05 2026-01-08 Immatics Biotechnologies Gmbh Means and methods for the quantification of target expression
WO2026033136A1 (en) 2024-08-09 2026-02-12 Immatics Biotechnologies Gmbh Advanced treatment modalities for anti-prame tcr-engineered immune cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156317A (en) * 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide

Also Published As

Publication number Publication date
IL165398A (en) 2013-04-30
DE10225139A1 (de) 2004-02-26
DE50310283D1 (de) 2008-09-18
CA2486738A1 (en) 2003-12-04
CY1108358T1 (el) 2014-02-12
ATE403874T1 (de) 2008-08-15
AU2003236645B2 (en) 2009-06-18
JP2005535299A (ja) 2005-11-24
DK1508047T3 (da) 2008-10-20
EP1508047A2 (de) 2005-02-23
PT1508047E (pt) 2008-10-02
ES2311710T3 (es) 2009-02-16
SI1508047T1 (sl) 2008-12-31
CA2486738C (en) 2011-07-12
WO2003100432A3 (de) 2004-06-03
WO2003100432A2 (de) 2003-12-04
AU2003236645A1 (en) 2003-12-12
EP1508047B1 (de) 2008-08-06

Similar Documents

Publication Publication Date Title
IL165398A0 (en) Method for identifying immunoreactive peptides
WO2003089904A3 (en) Aib1 as a prognostic marker and predictor of resistance to encocrine therapy
WO2004050707A3 (de) Tumorspezifische erkennungsmoleküle
WO2004001381A3 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
WO2002103532A3 (de) Verfahren zur bearbeitung von daten
DK1562941T3 (da) Trans-9,10-dehydroepothilon C og D, analoger deraf og fremstillingsmåder til fremstilling heraf
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
AU2003221704A1 (en) Immunogenic peptides, and method of identifying same
UA84284C2 (ru) Способы лечения, профилактики и диагностики инфекции helicobacter cerdo
ATE427127T1 (de) Bioaktive beschichtung fur medizinische vorrichtung mit keratin
WO2004105574A3 (en) Image guided radiation therapy
EP1412388A4 (en) HUMANIZED ANTIBODIES DERIVED FROM DD-3B6 / 22, SPECIFIC OF THE FIBRIN D-DIMER FRAGMENT
DK1290160T3 (da) Humane Pellino-polypeptider
WO2003073818A3 (en) Proteomic analysis of tumors for development of consultative report of therapeutic options
ATE427967T1 (de) Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea)
WO2003073351A3 (en) Screening process
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
WO2003069553A3 (en) Method of image analysis
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
WO2002024895A3 (en) Transcription factors and zinc finger proteins
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
NO20062657L (no) Cytokinantagonistmolekyler
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
WO2003029488A3 (en) A method for the early detection of cancer